ID   PTK6_HUMAN              Reviewed;         451 AA.
AC   Q13882; B2RCR3; B4DW46; Q58F01;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   12-OCT-2022, entry version 218.
DE   RecName: Full=Protein-tyrosine kinase 6;
DE            EC=2.7.10.2 {ECO:0000269|PubMed:12121988, ECO:0000269|PubMed:27480927, ECO:0000269|PubMed:27993680};
DE   AltName: Full=Breast tumor kinase;
DE   AltName: Full=Tyrosine-protein kinase BRK;
GN   Name=PTK6; Synonyms=BRK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Mammary tumor;
RX   PubMed=8036022;
RA   Mitchell P.J., Barker K.T., Martindale J.E., Kamalati T., Lowe P.N.,
RA   Page M.J., Gusterson B.A., Crompton M.R.;
RT   "Cloning and characterisation of cDNAs encoding a novel non-receptor
RT   tyrosine kinase, brk, expressed in human breast tumours.";
RL   Oncogene 9:2383-2390(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RX   PubMed=9333026; DOI=10.1038/sj.onc.1201292;
RA   Mitchell P.J., Barker K.T., Shipley J., Crompton M.R.;
RT   "Characterisation and chromosome mapping of the human non receptor tyrosine
RT   kinase gene, brk.";
RL   Oncogene 15:1497-1502(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Melanocyte;
RX   PubMed=9749526;
RA   Lee H.-Y., Kim M., Lee K.-H., Kang K.-N., Lee S.-T.;
RT   "Exon-intron structure of the human PTK6 gene demonstrates that PTK6
RT   constitutes a distinct family of non-receptor tyrosine kinase.";
RL   Mol. Cells 8:401-407(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Urinary bladder;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D.,
RA   Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G.,
RA   Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E.,
RA   Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D.,
RA   Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M.,
RA   Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D.,
RA   Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M.,
RA   Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A.,
RA   Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L.,
RA   Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L.,
RA   Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Blood;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   CHARACTERIZATION, INTERACTION WITH EGFR, AND MUTAGENESIS OF LYS-219 AND
RP   TYR-447.
RX   PubMed=8940083; DOI=10.1074/jbc.271.48.30956;
RA   Kamalati T., Jolin H.E., Mitchell P.J., Barker K.T., Jackson L.E.,
RA   Dean C.J., Page M.J., Gusterson B.A., Crompton M.R.;
RT   "Brk, a breast tumor-derived non-receptor protein-tyrosine kinase,
RT   sensitizes mammary epithelial cells to epidermal growth factor.";
RL   J. Biol. Chem. 271:30956-30963(1996).
RN   [8]
RP   TISSUE SPECIFICITY.
RX   PubMed=9185712;
RX   DOI=10.1002/(sici)1097-0215(19970611)71:6<1061::aid-ijc24>3.0.co;2-f;
RA   Easty D.J., Mitchell P.J., Patel K., Florenes V.A., Spritz R.A.,
RA   Bennett D.C.;
RT   "Loss of expression of receptor tyrosine kinase family genes PTK7 and SEK
RT   in metastatic melanoma.";
RL   Int. J. Cancer 71:1061-1065(1997).
RN   [9]
RP   FUNCTION, INTERACTION WITH STAP2, AND MUTAGENESIS OF TRP-44; TYR-66;
RP   ARG-105 AND LYS-219.
RX   PubMed=10980601; DOI=10.1038/sj.onc.1203775;
RA   Mitchell P.J., Sara E.A., Crompton M.R.;
RT   "A novel adaptor-like protein which is a substrate for the non-receptor
RT   tyrosine kinase, BRK.";
RL   Oncogene 19:4273-4282(2000).
RN   [10]
RP   SUBCELLULAR LOCATION, PHOSPHORYLATION AT TYR-447, AND INTERACTION WITH
RP   KHDRBS1.
RX   PubMed=10913193; DOI=10.1128/mcb.20.16.6114-6126.2000;
RA   Derry J.J., Richard S., Valderrama Carvajal H., Ye X., Vasioukhin V.,
RA   Cochrane A.W., Chen T., Tyner A.L.;
RT   "Sik (BRK) phosphorylates Sam68 in the nucleus and negatively regulates its
RT   RNA binding ability.";
RL   Mol. Cell. Biol. 20:6114-6126(2000).
RN   [11]
RP   PHOSPHORYLATION AT TYR-13; TYR-61; TYR-66; TYR-114; TYR-342 AND TYR-351,
RP   CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, MUTAGENESIS OF TYR-342
RP   AND TYR-447, ACTIVITY REGULATION, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=12121988; DOI=10.1074/jbc.m203877200;
RA   Qiu H., Miller W.T.;
RT   "Regulation of the nonreceptor tyrosine kinase Brk by autophosphorylation
RT   and by autoinhibition.";
RL   J. Biol. Chem. 277:34634-34641(2002).
RN   [12]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=12833144; DOI=10.1038/sj.onc.1206465;
RA   Derry J.J., Prins G.S., Ray V., Tyner A.L.;
RT   "Altered localization and activity of the intracellular tyrosine kinase
RT   BRK/Sik in prostate tumor cells.";
RL   Oncogene 22:4212-4220(2003).
RN   [13]
RP   FUNCTION, SUBCELLULAR LOCATION, MUTAGENESIS OF LYS-219 AND TYR-447, AND
RP   PHOSPHORYLATION.
RX   PubMed=15471878; DOI=10.1074/jbc.m409579200;
RA   Haegebarth A., Heap D., Bie W., Derry J.J., Richard S., Tyner A.L.;
RT   "The nuclear tyrosine kinase BRK/Sik phosphorylates and inhibits the RNA-
RT   binding activities of the Sam68-like mammalian proteins SLM-1 and SLM-2.";
RL   J. Biol. Chem. 279:54398-54404(2004).
RN   [14]
RP   FUNCTION IN CELL MIGRATION, FUNCTION IN PHOSPHORYLATION OF PXN, SUBCELLULAR
RP   LOCATION, AND INTERACTION WITH PXN.
RX   PubMed=15572663; DOI=10.1128/mcb.24.24.10558-10572.2004;
RA   Chen H.Y., Shen C.H., Tsai Y.T., Lin F.C., Huang Y.P., Chen R.H.;
RT   "Brk activates rac1 and promotes cell migration and invasion by
RT   phosphorylating paxillin.";
RL   Mol. Cell. Biol. 24:10558-10572(2004).
RN   [15]
RP   TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.
RX   PubMed=15509496; DOI=10.1016/j.oraloncology.2004.05.010;
RA   Petro B.J., Tan R.C., Tyner A.L., Lingen M.W., Watanabe K.;
RT   "Differential expression of the non-receptor tyrosine kinase BRK in oral
RT   squamous cell carcinoma and normal oral epithelium.";
RL   Oral Oncol. 40:1040-1047(2004).
RN   [16]
RP   FUNCTION IN PHOSPHORYLATION OF BTK, AND INTERACTION WITH BTK.
RX   PubMed=15539407; DOI=10.1074/jbc.m412038200;
RA   Zhang P., Ostrander J.H., Faivre E.J., Olsen A., Fitzsimmons D.,
RA   Lange C.A.;
RT   "Regulated association of protein kinase B/Akt with breast tumor kinase.";
RL   J. Biol. Chem. 280:1982-1991(2005).
RN   [17]
RP   MUTAGENESIS OF TRP-184, AND ACTIVITY REGULATION.
RX   PubMed=15961400; DOI=10.1074/jbc.m504568200;
RA   Kim H.I.E., Lee S.T.;
RT   "An intramolecular interaction between SH2-kinase linker and kinase domain
RT   is essential for the catalytic activity of protein-tyrosine kinase-6.";
RL   J. Biol. Chem. 280:28973-28980(2005).
RN   [18]
RP   FUNCTION IN PHOSPHORYLATION OF KHDRBS1.
RX   PubMed=16179349; DOI=10.1074/jbc.m505802200;
RA   Lukong K.E., Larocque D., Tyner A.L., Richard S.;
RT   "Tyrosine phosphorylation of sam68 by breast tumor kinase regulates
RT   intranuclear localization and cell cycle progression.";
RL   J. Biol. Chem. 280:38639-38647(2005).
RN   [19]
RP   INTERACTION WITH IRS4, AND ACTIVITY REGULATION.
RX   PubMed=15870689; DOI=10.1038/sj.onc.1208721;
RA   Qiu H., Zappacosta F., Su W., Annan R.S., Miller W.T.;
RT   "Interaction between Brk kinase and insulin receptor substrate-4.";
RL   Oncogene 24:5656-5664(2005).
RN   [20]
RP   TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.
RX   PubMed=16651629; DOI=10.2353/ajpath.2006.050521;
RA   Kasprzycka M., Majewski M., Wang Z.J., Ptasznik A., Wysocka M., Zhang Q.,
RA   Marzec M., Gimotty P., Crompton M.R., Wasik M.A.;
RT   "Expression and oncogenic role of Brk (PTK6/Sik) protein tyrosine kinase in
RT   lymphocytes.";
RL   Am. J. Pathol. 168:1631-1641(2006).
RN   [21]
RP   FUNCTION IN PHOSPHORYLATION OF STAT3, AND ACTIVITY REGULATION.
RX   PubMed=16568091; DOI=10.1038/sj.onc.1209501;
RA   Liu L., Gao Y., Qiu H., Miller W.T., Poli V., Reich N.C.;
RT   "Identification of STAT3 as a specific substrate of breast tumor kinase.";
RL   Oncogene 25:4904-4912(2006).
RN   [22]
RP   ACTIVITY REGULATION, AND MUTAGENESIS OF TRP-44.
RX   PubMed=17822667; DOI=10.1016/j.bbrc.2007.08.055;
RA   Kim H.I.E., Jung J., Lee E.S., Kim Y.C., Lee W., Lee S.T.;
RT   "Molecular dissection of the interaction between the SH3 domain and the
RT   SH2-Kinase Linker region in PTK6.";
RL   Biochem. Biophys. Res. Commun. 362:829-834(2007).
RN   [23]
RP   FUNCTION IN PHOSPHORYLATION OF STAT5B.
RX   PubMed=17997837; DOI=10.1186/bcr1794;
RA   Weaver A.M., Silva C.M.;
RT   "Signal transducer and activator of transcription 5b: a new target of
RT   breast tumor kinase/protein tyrosine kinase 6.";
RL   Breast Cancer Res. 9:R79-R79(2007).
RN   [24]
RP   FUNCTION IN PHOSPHORYLATION OF ARHGAP35.
RX   PubMed=18829532; DOI=10.1158/0008-5472.can-08-0997;
RA   Shen C.H., Chen H.Y., Lin M.S., Li F.Y., Chang C.C., Kuo M.L.,
RA   Settleman J., Chen R.H.;
RT   "Breast tumor kinase phosphorylates p190RhoGAP to regulate rho and ras and
RT   promote breast carcinoma growth, migration, and invasion.";
RL   Cancer Res. 68:7779-7787(2008).
RN   [25]
RP   INTERACTION WITH ADAM15.
RX   PubMed=18296648; DOI=10.1158/1541-7786.mcr-07-2028;
RA   Zhong J.L., Poghosyan Z., Pennington C.J., Scott X., Handsley M.M.,
RA   Warn A., Gavrilovic J., Honert K., Kruger A., Span P.N., Sweep F.C.,
RA   Edwards D.R.;
RT   "Distinct functions of natural ADAM-15 cytoplasmic domain variants in human
RT   mammary carcinoma.";
RL   Mol. Cancer Res. 6:383-394(2008).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-114, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [27]
RP   INTERACTION WITH ERBB2.
RX   PubMed=18719096; DOI=10.1073/pnas.0805009105;
RA   Xiang B., Chatti K., Qiu H., Lakshmi B., Krasnitz A., Hicks J., Yu M.,
RA   Miller W.T., Muthuswamy S.K.;
RT   "Brk is coamplified with ErbB2 to promote proliferation in breast cancer.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:12463-12468(2008).
RN   [28]
RP   INTERACTION WITH SFPQ.
RX   PubMed=19439179; DOI=10.1016/j.cellsig.2009.04.008;
RA   Lukong K.E., Huot M.E., Richard S.;
RT   "BRK phosphorylates PSF promoting its cytoplasmic localization and cell
RT   cycle arrest.";
RL   Cell. Signal. 21:1415-1422(2009).
RN   [29]
RP   REVIEW ON FUNCTION.
RX   PubMed=20193745; DOI=10.1016/j.bbcan.2010.02.003;
RA   Brauer P.M., Tyner A.L.;
RT   "Building a better understanding of the intracellular tyrosine kinase PTK6
RT   - BRK by BRK.";
RL   Biochim. Biophys. Acta 1806:66-73(2010).
RN   [30]
RP   PHOSPHORYLATION OF CTNNB1, AND INTERACTION WITH CTNNB1.
RX   PubMed=20026641; DOI=10.1242/jcs.053264;
RA   Palka-Hamblin H.L., Gierut J.J., Bie W., Brauer P.M., Zheng Y., Asara J.M.,
RA   Tyner A.L.;
RT   "Identification of beta-catenin as a target of the intracellular tyrosine
RT   kinase PTK6.";
RL   J. Cell Sci. 123:236-245(2010).
RN   [31]
RP   FUNCTION (ISOFORM 2), AND INTERACTION (ISOFORM 2) WITH KHDRBS1 AND CTNNB1.
RX   PubMed=21479203; DOI=10.1371/journal.pone.0014789;
RA   Brauer P.M., Zheng Y., Evans M.D., Dominguez-Brauer C., Peehl D.M.,
RA   Tyner A.L.;
RT   "The alternative splice variant of protein tyrosine kinase 6 negatively
RT   regulates growth and enhances PTK6-mediated inhibition of beta-catenin.";
RL   PLoS ONE 6:E14789-E14789(2011).
RN   [32]
RP   STRUCTURE BY NMR OF 75-174.
RX   PubMed=15056653; DOI=10.1074/jbc.m313185200;
RA   Hong E., Shin J., Kim H.I., Lee S.T., Lee W.;
RT   "Solution structure and backbone dynamics of the non-receptor protein-
RT   tyrosine kinase-6 Src homology 2 domain.";
RL   J. Biol. Chem. 279:29700-29708(2004).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (2.33 ANGSTROMS) OF 185-446, CATALYTIC ACTIVITY, AND
RP   MUTAGENESIS OF LYS-219.
RX   PubMed=27480927; DOI=10.1016/j.bbrc.2016.07.121;
RA   Thakur M.K., Kumar A., Birudukota S., Swaminathan S., Tyagi R., Gosu R.;
RT   "Crystal structure of the kinase domain of human protein tyrosine kinase 6
RT   (PTK6) at 2.33 A resolution.";
RL   Biochem. Biophys. Res. Commun. 478:637-642(2016).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 185-446 IN COMPLEXES WITH
RP   INHIBITORS, AND CATALYTIC ACTIVITY.
RX   PubMed=27993680; DOI=10.1016/j.bbrc.2016.12.030;
RA   Thakur M.K., Birudukota S., Swaminathan S., Battula S.K., Vadivelu S.,
RA   Tyagi R., Gosu R.;
RT   "Co-crystal structures of PTK6: With Dasatinib at 2.24 A, with novel
RT   imidazo[1,2-a]pyrazin-8-amine derivative inhibitor at 1.70 A resolution.";
RL   Biochem. Biophys. Res. Commun. 482:1289-1295(2017).
RN   [35]
RP   VARIANTS [LARGE SCALE ANALYSIS] PHE-16 AND THR-436.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Non-receptor tyrosine-protein kinase implicated in the
CC       regulation of a variety of signaling pathways that control the
CC       differentiation and maintenance of normal epithelia, as well as tumor
CC       growth. Function seems to be context dependent and differ depending on
CC       cell type, as well as its intracellular localization. A number of
CC       potential nuclear and cytoplasmic substrates have been identified.
CC       These include the RNA-binding proteins: KHDRBS1/SAM68, KHDRBS2/SLM1,
CC       KHDRBS3/SLM2 and SFPQ/PSF; transcription factors: STAT3 and STAT5A/B
CC       and a variety of signaling molecules: ARHGAP35/p190RhoGAP,
CC       PXN/paxillin, BTK/ATK, STAP2/BKS. Associates also with a variety of
CC       proteins that are likely upstream of PTK6 in various signaling
CC       pathways, or for which PTK6 may play an adapter-like role. These
CC       proteins include ADAM15, EGFR, ERBB2, ERBB3 and IRS4. In normal or non-
CC       tumorigenic tissues, PTK6 promotes cellular differentiation and
CC       apoptosis. In tumors PTK6 contributes to cancer progression by
CC       sensitizing cells to mitogenic signals and enhancing proliferation,
CC       anchorage-independent survival and migration/invasion. Association with
CC       EGFR, ERBB2, ERBB3 may contribute to mammary tumor development and
CC       growth through enhancement of EGF-induced signaling via BTK/AKT and PI3
CC       kinase. Contributes to migration and proliferation by contributing to
CC       EGF-mediated phosphorylation of ARHGAP35/p190RhoGAP, which promotes
CC       association with RASA1/p120RasGAP, inactivating RhoA while activating
CC       RAS. EGF stimulation resulted in phosphorylation of PNX/Paxillin by
CC       PTK6 and activation of RAC1 via CRK/CrKII, thereby promoting migration
CC       and invasion. PTK6 activates STAT3 and STAT5B to promote proliferation.
CC       Nuclear PTK6 may be important for regulating growth in normal
CC       epithelia, while cytoplasmic PTK6 might activate oncogenic signaling
CC       pathways.
CC   -!- FUNCTION: Isoform 2 inhibits PTK6 phosphorylation and PTK6 association
CC       with other tyrosine-phosphorylated proteins.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.2;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028,
CC         ECO:0000269|PubMed:12121988, ECO:0000269|PubMed:27480927,
CC         ECO:0000269|PubMed:27993680};
CC   -!- ACTIVITY REGULATION: Activated by EGF, NRG1 and IGF1. Inhibited by
CC       SOCS3 to phosphorylate STAT3. Stabilized in the inactive form by an
CC       association between the SH3 domain and the SH2-TK linker region.
CC       Interaction between Trp-184 within SH2-TK linker region and the
CC       catalytic domain appears essential for positive regulation of kinase
CC       activity. {ECO:0000269|PubMed:12121988, ECO:0000269|PubMed:15870689,
CC       ECO:0000269|PubMed:15961400, ECO:0000269|PubMed:16568091,
CC       ECO:0000269|PubMed:17822667}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=83 uM for ATP {ECO:0000269|PubMed:12121988};
CC         Vmax=37 nmol/min/mg enzyme {ECO:0000269|PubMed:12121988};
CC   -!- SUBUNIT: Interacts with GAP-A.p65 (By similarity). Interacts (via SH3
CC       and SH2 domains) with KHDRBS1. Interacts (via SH3 and SH2 domains) with
CC       phosphorylated IRS4. Interacts with ADAM15. Interacts (via SH3 domain)
CC       with SFPQ. Interacts with EGFR and ERBB2. Interacts with STAP2.
CC       Interacts with PNX. Interacts with SFPQ. Interacts with PTK/ATK.
CC       Interacts with CTNNB1. {ECO:0000250, ECO:0000269|PubMed:10913193,
CC       ECO:0000269|PubMed:10980601, ECO:0000269|PubMed:15539407,
CC       ECO:0000269|PubMed:15572663, ECO:0000269|PubMed:15870689,
CC       ECO:0000269|PubMed:18296648, ECO:0000269|PubMed:18719096,
CC       ECO:0000269|PubMed:19439179, ECO:0000269|PubMed:20026641,
CC       ECO:0000269|PubMed:8940083}.
CC   -!- INTERACTION:
CC       Q13882; Q08043: ACTN3; NbExp=3; IntAct=EBI-1383632, EBI-2880652;
CC       Q13882; Q3KP44: ANKRD55; NbExp=3; IntAct=EBI-1383632, EBI-14493093;
CC       Q13882; Q13191: CBLB; NbExp=3; IntAct=EBI-1383632, EBI-744027;
CC       Q13882; Q16543: CDC37; NbExp=4; IntAct=EBI-1383632, EBI-295634;
CC       Q13882; Q92841: DDX17; NbExp=4; IntAct=EBI-1383632, EBI-746012;
CC       Q13882; Q8N9I9: DTX3; NbExp=3; IntAct=EBI-1383632, EBI-2340258;
CC       Q13882; Q5JST6: EFHC2; NbExp=7; IntAct=EBI-1383632, EBI-2349927;
CC       Q13882; P04626: ERBB2; NbExp=4; IntAct=EBI-1383632, EBI-641062;
CC       Q13882; O00471: EXOC5; NbExp=6; IntAct=EBI-1383632, EBI-949824;
CC       Q13882; O14526: FCHO1; NbExp=4; IntAct=EBI-1383632, EBI-719823;
CC       Q13882; Q13480: GAB1; NbExp=6; IntAct=EBI-1383632, EBI-517684;
CC       Q13882; P08238: HSP90AB1; NbExp=3; IntAct=EBI-1383632, EBI-352572;
CC       Q13882; P42858: HTT; NbExp=4; IntAct=EBI-1383632, EBI-466029;
CC       Q13882; Q9UKT9: IKZF3; NbExp=3; IntAct=EBI-1383632, EBI-747204;
CC       Q13882; Q5VWX1: KHDRBS2; NbExp=4; IntAct=EBI-1383632, EBI-742808;
CC       Q13882; Q5T5P2-6: KIAA1217; NbExp=3; IntAct=EBI-1383632, EBI-10188326;
CC       Q13882; P10721: KIT; NbExp=4; IntAct=EBI-1383632, EBI-1379503;
CC       Q13882; O14770-4: MEIS2; NbExp=3; IntAct=EBI-1383632, EBI-8025850;
CC       Q13882; Q13064: MKRN3; NbExp=3; IntAct=EBI-1383632, EBI-2340269;
CC       Q13882; Q8TDC0: MYOZ3; NbExp=3; IntAct=EBI-1383632, EBI-5662487;
CC       Q13882; P78337: PITX1; NbExp=3; IntAct=EBI-1383632, EBI-748265;
CC       Q13882; Q9NQX0: PRDM6; NbExp=3; IntAct=EBI-1383632, EBI-11320284;
CC       Q13882; Q13882: PTK6; NbExp=3; IntAct=EBI-1383632, EBI-1383632;
CC       Q13882; Q04864: REL; NbExp=3; IntAct=EBI-1383632, EBI-307352;
CC       Q13882; P23246: SFPQ; NbExp=5; IntAct=EBI-1383632, EBI-355453;
CC       Q13882; Q13239-3: SLA; NbExp=3; IntAct=EBI-1383632, EBI-17630587;
CC       Q13882; O00401: WASL; NbExp=3; IntAct=EBI-1383632, EBI-957615;
CC       Q13882; Q9BYN7: ZNF341; NbExp=3; IntAct=EBI-1383632, EBI-9089622;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cell projection, ruffle.
CC       Membrane {ECO:0000250}. Note=Colocalizes with KHDRBS1, KHDRBS2 or
CC       KHDRBS3, within the nucleus. Nuclear localization in epithelial cells
CC       of normal prostate but cytoplasmic localization in cancer prostate.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q13882-1; Sequence=Displayed;
CC       Name=2; Synonyms=ALT-PTK6, LambdaM5;
CC         IsoId=Q13882-2; Sequence=VSP_042066, VSP_042067;
CC   -!- TISSUE SPECIFICITY: Epithelia-specific. Very high level in colon and
CC       high levels in small intestine and prostate, and low levels in some
CC       fetal tissues. Not expressed in breast or ovarian tissue but expressed
CC       in high percentage of breast and ovarian cancers. Also overexpressed in
CC       some metastatic melanomas, lymphomas, colon cancers, squamous cell
CC       carcinomas and prostate cancers. Also found in melanocytes. Not
CC       expressed in heart, brain, placenta, lung, liver, skeletal muscle,
CC       kidney and pancreas. Isoform 2 is present in prostate epithelial cell
CC       lines derived from normal prostate and prostate adenocarcinomas, as
CC       well as in a variety of cell lines. {ECO:0000269|PubMed:12833144,
CC       ECO:0000269|PubMed:15509496, ECO:0000269|PubMed:16651629,
CC       ECO:0000269|PubMed:9185712}.
CC   -!- DOMAIN: The SH3 domain plays a major role in substrate interactions.
CC       The SH2 domain of PTK6 plays a role in protein-protein interactions,
CC       but is likely more important for the regulation of catalytic activity.
CC   -!- PTM: Autophosphorylated. Autophosphorylation of Tyr-342 leads to an
CC       increase of kinase activity. Tyr-447 binds to the SH2 domain when
CC       phosphorylated and negatively regulates kinase activity.
CC       {ECO:0000269|PubMed:10913193, ECO:0000269|PubMed:12121988,
CC       ECO:0000269|PubMed:15471878, ECO:0000269|PubMed:20026641}.
CC   -!- MISCELLANEOUS: The inhibitors bind to the ATP-binding pocket.
CC       {ECO:0000269|PubMed:27993680}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. BRK/PTK6/SIK subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAG62908.1; Type=Erroneous translation; Note=Wrong choice of CDS.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X78549; CAA55295.1; -; mRNA.
DR   EMBL; U61412; AAC34935.1; -; Genomic_DNA.
DR   EMBL; U61406; AAC34935.1; JOINED; Genomic_DNA.
DR   EMBL; U61407; AAC34935.1; JOINED; Genomic_DNA.
DR   EMBL; U61408; AAC34935.1; JOINED; Genomic_DNA.
DR   EMBL; U61409; AAC34935.1; JOINED; Genomic_DNA.
DR   EMBL; U61410; AAC34935.1; JOINED; Genomic_DNA.
DR   EMBL; U61411; AAC34935.1; JOINED; Genomic_DNA.
DR   EMBL; AK315232; BAG37660.1; -; mRNA.
DR   EMBL; AK301364; BAG62908.1; ALT_SEQ; mRNA.
DR   EMBL; AL121829; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC035843; AAH35843.1; -; mRNA.
DR   CCDS; CCDS13524.1; -. [Q13882-1]
DR   CCDS; CCDS74750.1; -. [Q13882-2]
DR   PIR; S49016; S49016.
DR   RefSeq; NP_001243287.1; NM_001256358.1. [Q13882-2]
DR   RefSeq; NP_005966.1; NM_005975.3. [Q13882-1]
DR   PDB; 1RJA; NMR; -; A=75-174.
DR   PDB; 2KGT; NMR; -; A=1-72.
DR   PDB; 5D7V; X-ray; 2.33 A; A/B/C/D=185-446.
DR   PDB; 5DA3; X-ray; 1.70 A; A=185-446.
DR   PDB; 5H2U; X-ray; 2.24 A; A/B/C/D=185-446.
DR   PDB; 6CZ2; X-ray; 2.50 A; A=182-443.
DR   PDB; 6CZ3; X-ray; 1.80 A; A=182-443.
DR   PDB; 6CZ4; X-ray; 1.50 A; A=182-443.
DR   PDBsum; 1RJA; -.
DR   PDBsum; 2KGT; -.
DR   PDBsum; 5D7V; -.
DR   PDBsum; 5DA3; -.
DR   PDBsum; 5H2U; -.
DR   PDBsum; 6CZ2; -.
DR   PDBsum; 6CZ3; -.
DR   PDBsum; 6CZ4; -.
DR   AlphaFoldDB; Q13882; -.
DR   BMRB; Q13882; -.
DR   SMR; Q13882; -.
DR   BioGRID; 111720; 94.
DR   DIP; DIP-39785N; -.
DR   IntAct; Q13882; 74.
DR   MINT; Q13882; -.
DR   STRING; 9606.ENSP00000442460; -.
DR   BindingDB; Q13882; -.
DR   ChEMBL; CHEMBL4601; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB11800; Tivozanib.
DR   DrugBank; DB05294; Vandetanib.
DR   DrugBank; DB15035; Zanubrutinib.
DR   DrugCentral; Q13882; -.
DR   GuidetoPHARMACOLOGY; 2182; -.
DR   iPTMnet; Q13882; -.
DR   PhosphoSitePlus; Q13882; -.
DR   BioMuta; PTK6; -.
DR   DMDM; 8928302; -.
DR   EPD; Q13882; -.
DR   jPOST; Q13882; -.
DR   MassIVE; Q13882; -.
DR   MaxQB; Q13882; -.
DR   PaxDb; Q13882; -.
DR   PeptideAtlas; Q13882; -.
DR   PRIDE; Q13882; -.
DR   ProteomicsDB; 59709; -. [Q13882-1]
DR   ProteomicsDB; 59710; -. [Q13882-2]
DR   Antibodypedia; 29774; 543 antibodies from 37 providers.
DR   DNASU; 5753; -.
DR   Ensembl; ENST00000217185.3; ENSP00000217185.3; ENSG00000101213.7. [Q13882-2]
DR   Ensembl; ENST00000542869.3; ENSP00000442460.2; ENSG00000101213.7. [Q13882-1]
DR   GeneID; 5753; -.
DR   KEGG; hsa:5753; -.
DR   MANE-Select; ENST00000542869.3; ENSP00000442460.2; NM_005975.4; NP_005966.1.
DR   UCSC; uc002yfg.5; human. [Q13882-1]
DR   CTD; 5753; -.
DR   DisGeNET; 5753; -.
DR   GeneCards; PTK6; -.
DR   HGNC; HGNC:9617; PTK6.
DR   HPA; ENSG00000101213; Tissue enhanced (esophagus, skin, vagina).
DR   MIM; 602004; gene.
DR   neXtProt; NX_Q13882; -.
DR   OpenTargets; ENSG00000101213; -.
DR   PharmGKB; PA33960; -.
DR   VEuPathDB; HostDB:ENSG00000101213; -.
DR   eggNOG; KOG0197; Eukaryota.
DR   GeneTree; ENSGT00940000161218; -.
DR   HOGENOM; CLU_000288_7_2_1; -.
DR   InParanoid; Q13882; -.
DR   OMA; VRHYRIW; -.
DR   OrthoDB; 539311at2759; -.
DR   PhylomeDB; Q13882; -.
DR   TreeFam; TF351634; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   PathwayCommons; Q13882; -.
DR   Reactome; R-HSA-187577; SCF(Skp2)-mediated degradation of p27/p21.
DR   Reactome; R-HSA-69231; Cyclin D associated events in G1.
DR   Reactome; R-HSA-8847993; ERBB2 Activates PTK6 Signaling.
DR   Reactome; R-HSA-8849468; PTK6 Regulates Proteins Involved in RNA Processing.
DR   Reactome; R-HSA-8849469; PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1.
DR   Reactome; R-HSA-8849470; PTK6 Regulates Cell Cycle.
DR   Reactome; R-HSA-8849471; PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases.
DR   Reactome; R-HSA-8849472; PTK6 Down-Regulation.
DR   Reactome; R-HSA-8849473; PTK6 Expression.
DR   Reactome; R-HSA-8849474; PTK6 Activates STAT3.
DR   Reactome; R-HSA-8857538; PTK6 promotes HIF1A stabilization.
DR   Reactome; R-HSA-9707564; Cytoprotection by HMOX1.
DR   SABIO-RK; Q13882; -.
DR   SignaLink; Q13882; -.
DR   SIGNOR; Q13882; -.
DR   BioGRID-ORCS; 5753; 16 hits in 1102 CRISPR screens.
DR   EvolutionaryTrace; Q13882; -.
DR   GeneWiki; PTK6; -.
DR   GenomeRNAi; 5753; -.
DR   Pharos; Q13882; Tchem.
DR   PRO; PR:Q13882; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   RNAct; Q13882; protein.
DR   Bgee; ENSG00000101213; Expressed in esophagus squamous epithelium and 125 other tissues.
DR   Genevisible; Q13882; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0016604; C:nuclear body; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0001726; C:ruffle; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; EXP:Reactome.
DR   GO; GO:0005102; F:signaling receptor binding; IBA:GO_Central.
DR   GO; GO:0030154; P:cell differentiation; IBA:GO_Central.
DR   GO; GO:0016477; P:cell migration; IDA:UniProtKB.
DR   GO; GO:0071300; P:cellular response to retinoic acid; IMP:BHF-UCL.
DR   GO; GO:0038128; P:ERBB2 signaling pathway; TAS:Reactome.
DR   GO; GO:0045087; P:innate immune response; IBA:GO_Central.
DR   GO; GO:0060575; P:intestinal epithelial cell differentiation; IEA:Ensembl.
DR   GO; GO:0045926; P:negative regulation of growth; IEA:Ensembl.
DR   GO; GO:0061099; P:negative regulation of protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0045787; P:positive regulation of cell cycle; TAS:Reactome.
DR   GO; GO:0045742; P:positive regulation of epidermal growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IMP:BHF-UCL.
DR   GO; GO:0042531; P:positive regulation of tyrosine phosphorylation of STAT protein; TAS:Reactome.
DR   GO; GO:0046777; P:protein autophosphorylation; IMP:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   GO; GO:0007260; P:tyrosine phosphorylation of STAT protein; IDA:UniProtKB.
DR   CDD; cd10358; SH2_PTK6_Brk; 1.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR035846; PTK6_SH2.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR036860; SH2_dom_sf.
DR   InterPro; IPR036028; SH3-like_dom_sf.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF00018; SH3_1; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00452; SH3DOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00326; SH3; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell projection;
KW   Cytoplasm; Kinase; Membrane; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Reference proteome; SH2 domain; SH3 domain; Transferase;
KW   Tyrosine-protein kinase.
FT   CHAIN           1..451
FT                   /note="Protein-tyrosine kinase 6"
FT                   /id="PRO_0000088133"
FT   DOMAIN          8..72
FT                   /note="SH3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00192"
FT   DOMAIN          78..170
FT                   /note="SH2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00191"
FT   DOMAIN          191..445
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          171..190
FT                   /note="Linker"
FT   ACT_SITE        312
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         197..205
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         219
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000305|PubMed:27480927, ECO:0000305|PubMed:27993680"
FT   MOD_RES         13
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:12121988"
FT   MOD_RES         61
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:12121988"
FT   MOD_RES         66
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:12121988"
FT   MOD_RES         114
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:12121988,
FT                   ECO:0007744|PubMed:18691976"
FT   MOD_RES         342
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:12121988"
FT   MOD_RES         351
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:12121988"
FT   MOD_RES         447
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:10913193"
FT   VAR_SEQ         78..134
FT                   /note="WFFGCISRSEAVRRLQAEGNATGAFLIRVSEKPSADYVLSVRDTQAVRHYKI
FT                   WRRAG -> AGHAGCAALQDLAACRGPAAPERGGVLPQPARACELPQGPEPVPRPAAGR
FT                   ALPEARA (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:9333026"
FT                   /id="VSP_042066"
FT   VAR_SEQ         135..451
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:9333026"
FT                   /id="VSP_042067"
FT   VARIANT         16
FT                   /note="L -> F (in a renal papillary sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041760"
FT   VARIANT         436
FT                   /note="A -> T (in dbSNP:rs56145017)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041761"
FT   MUTAGEN         44
FT                   /note="W->A: Strong decrease in STAP2 phosphorylation.
FT                   Markedly decreased interaction between SH3 domain the
FT                   linker region."
FT                   /evidence="ECO:0000269|PubMed:10980601,
FT                   ECO:0000269|PubMed:17822667"
FT   MUTAGEN         66
FT                   /note="Y->A: Decrease in STAP2 phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:10980601"
FT   MUTAGEN         105
FT                   /note="R->L: Decrease in STAP2 phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:10980601"
FT   MUTAGEN         184
FT                   /note="W->A: Abrogates interaction between PTK6-domain
FT                   kinase and PTK6-linker. Abrogates autophosphorylation and
FT                   phosphorylation of KHDRBS1."
FT                   /evidence="ECO:0000269|PubMed:15961400"
FT   MUTAGEN         219
FT                   /note="K->M: Abolishes kinase activity and cell
FT                   transformation, and phosphorylation of STAP2."
FT                   /evidence="ECO:0000269|PubMed:10980601,
FT                   ECO:0000269|PubMed:15471878, ECO:0000269|PubMed:8940083"
FT   MUTAGEN         219
FT                   /note="K->R: Abolishes kinase activity."
FT                   /evidence="ECO:0000269|PubMed:27480927"
FT   MUTAGEN         342
FT                   /note="Y->A: 3-fold lower specific kinase activity.
FT                   Decreased, but still significant, autophosphorylation.
FT                   Decreased, but still significant, autophosphorylation; when
FT                   associated with A-447."
FT                   /evidence="ECO:0000269|PubMed:12121988"
FT   MUTAGEN         447
FT                   /note="Y->F: Decrease in transforming potential and
FT                   increase in the kinase activity level. Decreased, but still
FT                   significant, autophosphorylation; when associated with
FT                   A-342."
FT                   /evidence="ECO:0000269|PubMed:12121988,
FT                   ECO:0000269|PubMed:15471878, ECO:0000269|PubMed:8940083"
FT   STRAND          12..14
FT                   /evidence="ECO:0007829|PDB:2KGT"
FT   STRAND          35..40
FT                   /evidence="ECO:0007829|PDB:2KGT"
FT   STRAND          45..50
FT                   /evidence="ECO:0007829|PDB:2KGT"
FT   STRAND          56..62
FT                   /evidence="ECO:0007829|PDB:2KGT"
FT   TURN            64..66
FT                   /evidence="ECO:0007829|PDB:2KGT"
FT   STRAND          67..70
FT                   /evidence="ECO:0007829|PDB:2KGT"
FT   HELIX           85..92
FT                   /evidence="ECO:0007829|PDB:1RJA"
FT   STRAND          102..106
FT                   /evidence="ECO:0007829|PDB:1RJA"
FT   STRAND          108..112
FT                   /evidence="ECO:0007829|PDB:1RJA"
FT   STRAND          114..118
FT                   /evidence="ECO:0007829|PDB:1RJA"
FT   STRAND          125..131
FT                   /evidence="ECO:0007829|PDB:1RJA"
FT   STRAND          133..135
FT                   /evidence="ECO:0007829|PDB:1RJA"
FT   STRAND          137..140
FT                   /evidence="ECO:0007829|PDB:1RJA"
FT   STRAND          143..147
FT                   /evidence="ECO:0007829|PDB:1RJA"
FT   HELIX           148..157
FT                   /evidence="ECO:0007829|PDB:1RJA"
FT   STRAND          162..164
FT                   /evidence="ECO:0007829|PDB:1RJA"
FT   HELIX           188..190
FT                   /evidence="ECO:0007829|PDB:6CZ4"
FT   STRAND          191..200
FT                   /evidence="ECO:0007829|PDB:6CZ4"
FT   STRAND          203..210
FT                   /evidence="ECO:0007829|PDB:6CZ4"
FT   TURN            211..213
FT                   /evidence="ECO:0007829|PDB:6CZ4"
FT   STRAND          214..221
FT                   /evidence="ECO:0007829|PDB:6CZ4"
FT   HELIX           223..225
FT                   /evidence="ECO:0007829|PDB:6CZ4"
FT   HELIX           229..240
FT                   /evidence="ECO:0007829|PDB:6CZ4"
FT   STRAND          250..254
FT                   /evidence="ECO:0007829|PDB:6CZ4"
FT   STRAND          256..264
FT                   /evidence="ECO:0007829|PDB:6CZ4"
FT   STRAND          268..271
FT                   /evidence="ECO:0007829|PDB:6CZ2"
FT   HELIX           272..278
FT                   /evidence="ECO:0007829|PDB:6CZ4"
FT   TURN            281..283
FT                   /evidence="ECO:0007829|PDB:5DA3"
FT   HELIX           286..305
FT                   /evidence="ECO:0007829|PDB:6CZ4"
FT   HELIX           315..317
FT                   /evidence="ECO:0007829|PDB:6CZ4"
FT   STRAND          318..320
FT                   /evidence="ECO:0007829|PDB:6CZ4"
FT   HELIX           322..324
FT                   /evidence="ECO:0007829|PDB:5DA3"
FT   STRAND          326..328
FT                   /evidence="ECO:0007829|PDB:6CZ4"
FT   TURN            334..336
FT                   /evidence="ECO:0007829|PDB:6CZ4"
FT   HELIX           339..342
FT                   /evidence="ECO:0007829|PDB:6CZ4"
FT   HELIX           345..348
FT                   /evidence="ECO:0007829|PDB:5DA3"
FT   HELIX           351..353
FT                   /evidence="ECO:0007829|PDB:6CZ4"
FT   HELIX           356..361
FT                   /evidence="ECO:0007829|PDB:6CZ4"
FT   HELIX           366..380
FT                   /evidence="ECO:0007829|PDB:6CZ4"
FT   TURN            381..384
FT                   /evidence="ECO:0007829|PDB:6CZ4"
FT   HELIX           393..402
FT                   /evidence="ECO:0007829|PDB:6CZ4"
FT   HELIX           414..423
FT                   /evidence="ECO:0007829|PDB:6CZ4"
FT   HELIX           428..430
FT                   /evidence="ECO:0007829|PDB:6CZ4"
FT   HELIX           434..441
FT                   /evidence="ECO:0007829|PDB:6CZ4"
FT   HELIX           442..444
FT                   /evidence="ECO:0007829|PDB:5D7V"
SQ   SEQUENCE   451 AA;  51834 MW;  CDCAC0EE242E1BD7 CRC64;
     MVSRDQAHLG PKYVGLWDFK SRTDEELSFR AGDVFHVARK EEQWWWATLL DEAGGAVAQG
     YVPHNYLAER ETVESEPWFF GCISRSEAVR RLQAEGNATG AFLIRVSEKP SADYVLSVRD
     TQAVRHYKIW RRAGGRLHLN EAVSFLSLPE LVNYHRAQSL SHGLRLAAPC RKHEPEPLPH
     WDDWERPREE FTLCRKLGSG YFGEVFEGLW KDRVQVAIKV ISRDNLLHQQ MLQSEIQAMK
     KLRHKHILAL YAVVSVGDPV YIITELMAKG SLLELLRDSD EKVLPVSELL DIAWQVAEGM
     CYLESQNYIH RDLAARNILV GENTLCKVGD FGLARLIKED VYLSHDHNIP YKWTAPEALS
     RGHYSTKSDV WSFGILLHEM FSRGQVPYPG MSNHEAFLRV DAGYRMPCPL ECPPSVHKLM
     LTCWCRDPEQ RPCFKALRER LSSFTSYENP T
//
